These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33166734)

  • 21. Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise.
    Rani N; Bharti S; Krishnamurthy B; Bhatia J; Sharma C; Kamal MA; Ojha S; Arya DS
    Curr Pharm Des; 2016; 22(28):4341-59. PubMed ID: 27238365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of naringin: an overview.
    Chen R; Qi QL; Wang MT; Li QY
    Pharm Biol; 2016 Dec; 54(12):3203-3210. PubMed ID: 27564838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naringin and Naringenin: Potential Multi-Target Agents for Alzheimer's Disease.
    Lu J; Chen J; Li SY; Pan GJ; Ou Y; Yuan LF; Jiang JP; Zeng LH; Zhao J
    Curr Med Sci; 2024 Oct; 44(5):867-882. PubMed ID: 39347923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of naringenin in liver diseases: Molecular mechanisms.
    Hernández-Aquino E; Muriel P
    World J Gastroenterol; 2018 Apr; 24(16):1679-1707. PubMed ID: 29713125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells.
    Dayarathne LA; Ranaweera SS; Natraj P; Rajan P; Lee YJ; Han CH
    J Vet Sci; 2021 Nov; 22(6):e92. PubMed ID: 34854271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin.
    Orallo F; Camiña M; Alvarez E; Basaran H; Lugnier C
    Planta Med; 2005 Feb; 71(2):99-107. PubMed ID: 15729616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies for gastric cancer: current status.
    Yoong J; Michael M; Leong T
    Drugs; 2011 Jul; 71(11):1367-84. PubMed ID: 21812503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies.
    Chen H; Gao Y; Wu J; Chen Y; Chen B; Hu J; Zhou J
    Cancer Lett; 2014 Nov; 354(1):5-11. PubMed ID: 25128647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma.
    Bie B; Sun J; Guo Y; Li J; Jiang W; Yang J; Huang C; Li Z
    Biomed Pharmacother; 2017 Sep; 93():1285-1291. PubMed ID: 28747003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Cheremisina OV; Volkov MY; Choynzonov EL; Gorbunov AK; Usynin EA
    Curr Drug Targets; 2020; 21(7):713-721. PubMed ID: 31775598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: A review.
    Shirani K; Yousefsani BS; Shirani M; Karimi G
    Phytother Res; 2020 Aug; 34(8):1734-1744. PubMed ID: 32067280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells.
    Arul D; Subramanian P
    Pathol Oncol Res; 2013 Oct; 19(4):763-70. PubMed ID: 23661153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinational strategies of metformin and chemotherapy in cancers.
    Zhang HH; Guo XL
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):13-26. PubMed ID: 27118574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naringenin as a potential immunomodulator in therapeutics.
    Zeng W; Jin L; Zhang F; Zhang C; Liang W
    Pharmacol Res; 2018 Sep; 135():122-126. PubMed ID: 30081177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents.
    Meiyanto E; Hermawan A; Anindyajati
    Asian Pac J Cancer Prev; 2012; 13(2):427-36. PubMed ID: 22524801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
    Bagnyukova TV; Serebriiskii IG; Zhou Y; Hopper-Borge EA; Golemis EA; Astsaturov I
    Cancer Biol Ther; 2010 Nov; 10(9):839-53. PubMed ID: 20935499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.